| 0 (0%) | 11-11 21:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 90.81 |
1-year : | 106.07 |
| Resists | First : | 77.75 |
Second : | 90.81 |
| Pivot price | 73.85 |
|||
| Supports | First : | 73.12 |
Second : | 70.26 |
| MAs | MA(5) : | 75.03 |
MA(20) : | 73.55 |
| MA(100) : | 67.29 |
MA(250) : | 62.79 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 91.9 |
D(3) : | 85.8 |
| RSI | RSI(14): 71.1 |
|||
| 52-week | High : | 77.75 | Low : | 48.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBP ] has closed Bollinger Bands are 25.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 77.85 - 78.14 | 78.14 - 78.37 |
| Low: | 75.23 - 75.6 | 75.6 - 75.89 |
| Close: | 77.2 - 77.77 | 77.77 - 78.23 |
Mon, 10 Nov 2025
(BBP) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Mon, 10 Nov 2025
Why BBP stock stays undervalued - July 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Fri, 07 Nov 2025
BBP's Lily Castka clinches program's first state girls tennis title - Newsday
Fri, 07 Nov 2025
Does Positive BBP-418 Trial Data Signal a Turning Point for BridgeBio Pharma's (BBIO) Growth Story? - Sahm
Tue, 28 Oct 2025
BridgeBio Pharma (BBIO) Is Up 13.0% After Positive Phase 3 BBP-418 Results in Muscular Dystrophy - Yahoo Finance
Mon, 27 Oct 2025
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|